Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(21 sites)
United States
City of Hope - Lennar, Irvine, California University of California, Davis Comprehensive Cancer Center, Sacramento, California Stanford Cancer Institute, Stanford, California Sarah Cannon Research Institute at HealthONE, Denver, Colorado Georgetown University Medical Center, Washington D.C., District of Columbia Sibley Memorial Hospital, Washington D.C., District of Columbia Sylvester Comprehensive Cancer Center, Miami, Florida Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Henry Ford Cancer Center, Detroit, Michigan Washington University, St Louis, Missouri Memorial Sloan Kettering Cancer Center, New York, New York OSU Brain and Spine Hospital, Columbus, Ohio SCRI Oncology Partners, Nashville, Tennessee The University of Texas MD Anderson Cancer Center, Houston, Texas NEXT Virginia, Fairfax, Virginia Fred Hutchinson Cancer Center, Seattle, Washington Australia
Chris O'Brien Lifehouse, Camperdown, New South Wales North Shore Health Hub, Saint Leonards, New South Wales Canada
Cross Cancer Institute, Edmonton, Alberta Princess Margaret Cancer Center - University Health Network, Toronto, Ontario